Replimune Group's (REPL) "Neutral" Rating Reiterated at Wedbush

Replimune Group (NASDAQ:REPL - Get Free Report)'s stock had its "neutral" rating reiterated by stock analysts at Wedbush in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They presently have a $4.00 price target on the stock, down from their prior price target of $19.00. Wedbush's price target points to a potential upside of 34.45% from the company's current price.

Other equities research analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. increased their target price on shares of Replimune Group from $16.00 to $19.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 16th. HC Wainwright reiterated a "buy" rating and set a $22.00 target price on shares of Replimune Group in a research report on Thursday, July 3rd. Piper Sandler increased their target price on shares of Replimune Group from $14.00 to $22.00 and gave the stock an "overweight" rating in a research report on Monday, June 2nd. Finally, Cantor Fitzgerald started coverage on shares of Replimune Group in a report on Friday, June 20th. They set an "overweight" rating on the stock. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $15.86.

Replimune Group Stock Performance

Shares of NASDAQ REPL traded down $9.36 during midday trading on Tuesday, hitting $2.98. The company's stock had a trading volume of 51,909,791 shares, compared to its average volume of 1,170,342. Replimune Group has a 1-year low of $2.69 and a 1-year high of $17.00. The firm's fifty day moving average price is $9.62 and its 200-day moving average price is $10.46. The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.95 and a current ratio of 7.95. The firm has a market cap of $229.33 million, a P/E ratio of -0.97 and a beta of 0.61.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its earnings results on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period last year, the company posted ($0.25) EPS. On average, sell-side analysts forecast that Replimune Group will post -2.97 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Philip Astley-Sparke sold 32,279 shares of the firm's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $260,168.74. Following the sale, the director directly owned 1,405,071 shares of the company's stock, valued at $11,324,872.26. This trade represents a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Christopher Sarchi sold 3,749 shares of Replimune Group stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total value of $30,179.45. Following the transaction, the insider owned 128,296 shares in the company, valued at approximately $1,032,782.80. The trade was a 2.84% decrease in their position. The disclosure for this sale can be found here. Insiders sold 74,907 shares of company stock worth $603,655 in the last three months. 8.80% of the stock is currently owned by company insiders.

Institutional Trading of Replimune Group

Several institutional investors and hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. grew its holdings in shares of Replimune Group by 20.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company's stock worth $6,729,000 after acquiring an additional 119,145 shares during the period. Optimize Financial Inc acquired a new stake in Replimune Group during the 1st quarter valued at $140,000. Exome Asset Management LLC lifted its stake in shares of Replimune Group by 438.6% during the 1st quarter. Exome Asset Management LLC now owns 294,846 shares of the company's stock worth $2,875,000 after purchasing an additional 240,108 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of Replimune Group during the 1st quarter worth $343,000. Finally, Parkman Healthcare Partners LLC raised its position in shares of Replimune Group by 9.3% in the 1st quarter. Parkman Healthcare Partners LLC now owns 950,399 shares of the company's stock worth $9,266,000 after buying an additional 80,640 shares during the period. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.